IHC: Use at a concentration of 10 μg/ml. WB: Use at a concentration of 0.5 - 1 μg/ml. Detects a band of approximately 4-5 kDa. Optimal dilutions/concentrations should be determined by the end user.
This antibody reacts with synthetic beta amyloid [A beta (40) and A beta (42)] in Western blots. This antibody does not react with recombinant beta amyloid (AA 601-744). Thus this antibody recognizes the N-termini of A beta (40) and A beta (42) specifically.
Preservative: None Constituents: 50% Glycerol, PBS. pH 7.2
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1 mg/ml (Please refer to the vial label for the specific concentration.)
Synthetic peptide, corresponding to amino acids 1-16 of beta Amyloid.
Protein A purified
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Amyloid Beta Precursor Protein,Aaa,Abeta,Abpp,Ad1,Appi,Ctfgamma,Cvap,Pn-Ii,Pn2,Prea4,App
Type I membrane protein
The cerebral and vascular plaques associated with Alzheimer's disease are mainly composed of Amyloid beta peptides. beta Amyloid is derived from cleavage of the Amyloid precursor protein and varies in length from 39 to 43 amino acids. beta Amyloid [1-40], beta Amyloid [1-42], and beta Amyloid [1-43] peptides result from cleavage of Amyloid precursor protein after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last Amyloid precursor protein processing step. beta Amyloid [1-40], beta Amyloid [1-42], and beta Amyloid [1-43] peptides are major constituents of the plaques and tangles that occur in Alzheimer's disease. beta Amyloid antibodies and peptides have been developed as tools for elucidating the biology of Alzheimer's disease.